Impaired expression of peroxisome proliferator-activated receptor γin ulcerative colitis

Gastroenterology

Volumn 124, Issue 5, 2003, Pages 1265-1276

  Dubuquoy, Laurent ^a   Å Jansson, Emmelie ^b   Deeb, Samir ^c   Rakotobe, Sabine ^d   Karoui, Mehdi ^a   Colombel, Jean Frederic ^a   Auwerx, Johan ^e   Pettersson, Sven ^b   Desreumaux, Pierre ^a,f  

^a INSERM   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CEMAGREF   (France)

^e INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BETA ACTIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR 4;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BACTERIUM; CELL STRAIN CACO 2; CLINICAL ARTICLE; COLITIS; COLON; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; DNA POLYMORPHISM; ENTERITIS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTESTINE FLORA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

EID: 0037847511     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00271-3     Document Type: Article

References (46)

1. Schoonjans K, Martin G, Staels B, Auwerx J, Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-166.
2. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
3. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
4. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, Desreumaux P, Auwerx J. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-340.
5. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-389.
6. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-838.
7. Carlo E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol 2000;164:966-972.
8. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin invest 2001;107:7-11.
9. Karlinger K, Gyorke T, Mako E, Mester A, Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000;35:154-167.
10. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-135.
11. Shanahan F. Crohn's disease. Lancet 2002;359:62-69.
12. Sandre C, Gleizes A, Forestier F, Gorges-Kergot R, Chilmonczyk S, Leonil J, Moreau MC, Labarre C. A peptide derived from bovine beta-casein modulates functional properties of bone marrow-derived macrophages from germ-free and human flora-associated mice. J Nutr 2001;131:2936-2942.
13. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997;388:394-397.
14. Shivananda S, Hordijk ML, Ten Kate FJ, Probert CS, Mayberry JF. Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications. Scand J Gastroenterol 1991;26:167-173.
15. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennet BL, Li JW, Young DB, Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: cytokine-activated IkB kinase essential for NF-κB activation. Science 1997;278:860-866.
16. de Rock E, Taylor N. An easy method of layering blood over Ficoil-Paque gradients. J Immunol Methods 1977;17:373-374.
17. Toy LS, Yio XY, Lin A, Honig S, Mayer L. Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. J Clin Invest 1997;100:2062-2071.
18. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997;113:118-126.
19. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319-1327.
20. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H, Hafraoui S, Emilie D, Ectors N, Peuchmaur M, Cortot A, Capron M, Auwerx J, Colombel JF. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73-81.
21. Pettersson S, Cook GP, Bruggemann M, Williams GT, Neuberger MS. A second B cell-specific enhancer 3′ of the immunoglobulin heavy-chain locus. Nature 1990;344:165-168.
22. Mason JO, Williams GT, Neuberger MS. The half-life of immunoglobulin MRNA increases during B-cell differentiation: a possible role for targeting to membrane-bound polysomes. Genes Dev 1988;2:1003-1011.
23. Gunning P, Ponte P, Okayama H, Engel J, Blau H, Kedes L. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol Cell Biol 1983;3:787-795.
24. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-18789.
25. Nevin DN, Brunzell JD, Deeb SS. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler Thromb 1994;14:869-873.
26. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167:1609-1616.
27. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPAR-gamma coactivator-1. Mol Cell 2001;8:971-982.
28. Berliner L, Redmond P, Purow E, Megna D, Sottile V. Computed tomography in Crohn's disease. Am J Gastroenterol 1982;77:548-553.
29. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996;222:844-851.
30. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
31. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435-440.
32. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-199.
33. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002;195:559-570.
34. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR4) in cultured human dermal endothelial cells. Differential expression of TLR4 and TLR-2 in endothelial cells. J Biol Chem 2000;275:11058-11063.
35. Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, Kim TH, Chae U, Song GG, Yoo DH, Kim SY, Sohn J. Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun 2001;17:215-221.
36. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann U, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001;120:460-469.
37. Straus DS, Pascual G, Li M, Welch JS. Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 2000;97:4844-4849.
38. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998;153:349-354.
39. Carlo E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7017.
40. Ehrhardt RO. New insights into the immunopathology of chronic inflammatory bowel disease. Semin Gastrointest Dis 1996;7:144-150.
41. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001;81:1031-1064.
42. Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem Biophys Res Commun 2002;293:827-831.
43. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000;272:380-385.
44. Fajas L, Debril MB, Auwerx J. PPAR gamma: an essential role in metabolic control. Nutr Metab Cardiovasc Dis 2001;11:64-69.
45. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease-'colitis indeterminate'. J Clin Pathol 1978;31:567-577.
46. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001;96:3323-3328.